Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; VET3 TGI (Primary) ; VET3 TGI (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Oesophageal cancer; Ovarian cancer; Renal cancer; Sarcoma; Solid tumours; Thymoma; Uterine cancer
  • Focus Adverse reactions; First in man
  • Acronyms STEALTH-001
  • Sponsors KaliVir Immunotherapeutics

Most Recent Events

  • 19 Nov 2025 According to KaliVir Immunotherapeutics media release, company announced a clinical trial collaboration and supply agreement with Roche to evaluate VET3-TGI in combination with Roche atezolizumab. The collaboration will support the expansion of this trial.
  • 01 Oct 2025 According to KaliVir Immunotherapeutics media release, the first cohort in the intravenous (IV) infusion arm of its STEALTH-001 (NCT06444815) clinical study, has been completed.
  • 22 May 2025 According to KaliVir Immunotherapeutics media release, today announced the successful completion of the first cohort in its STEALTH-001 study. Data Safety Committee reviewed Cohort 1 safety data from intratumoral patients and cleared dosing for the next intratumoral and intravenous cohorts.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top